Table 8.
TASC-II classification for the worst lesion treated and perioperative data according to the local perfusion of the ischemic ulcer.
| Perioperative data | P value | |||||
|---|---|---|---|---|---|---|
| DR+ (n = 46) | IRμ “through collaterals” (n = 22) | IRμ “without collaterals” (n = 17) | DR+ versus IR “through collaterals” | DR+ versus IRµ “without collaterals” | IRμ “through collaterals versus IRμ “without collaterals” | |
| TASC-B | 3 (6.5%) | 3 (13.6%) | 0 (0%) | 0.38 | 0.55 | 0.24 |
| TASC-C | 4 (8.7%) | 3 (13.6%) | 4 (23.5%) | 0.67 | 0.19 | 0.67 |
| TASC-D | 39 (84.8%) | 16 (72.7%) | 13 (76.5%) | 0.23 | 0.46 | 0.79 |
| Combined treatment* | 20 (43.5%) | 7 (31.8%) | 3 (17.6%) | 0.06 | 0.009 | 0.46 |
| Debridement | 4 (8.7%) | 2 (9.1%) | 2 (11.8%) | 0.95 | 0.65 | 0.78 |
| Minor amputation | 12 (26.1%) | 7 (31.8%) | 3 (17.6%) | 0.62 | 0.74 | 0.46 |
| Multiple revascularization | 31 (67.4%) | 8 (36.4%) | 7 (41.2%) | 0.01 | 0.06 | 0.75 |
| Runoff 1 | 28 (60.9%) | 20 (90.9%) | 16 (94.1%) | 0.01 | 0.01 | 0.70 |
| Runoff > 1 | 18 (39.1%) | 2 (9.1%) | 1 (5.9%) | 0.01 | 0.01 | 0.70 |
| Postoperative ABI# | 0.85 (0.70–0.95) | 0.91 (0.82–0.95) | 0.80 (0.65–0.91) | 0.30 | 0.79 | 0.48 |
| MACE† at 30 days | 1 (2.2%) | 2 (9.1%) | 0 (0%) | 0.24 | 0.54 | 0.49 |
| MALE& at 30 days | 1 (2.2%) | 1 (4.5%) | 1 (5.9%) | 0.54 | 0.47 | 0.85 |
| Major amputation at 30 days | 1 (2.2%) | 1 (4.5%) | 0 (0%) | 0.54 | 0.73 | 0.37 |
*Combined treatment: combined treatment of the femoropopliteal and the infrapopliteal sector; #ABI: ankle-brachial index; †MACE: major adverse cardiovascular event; &MALE: major adverse limb event; +DR: direct revascularization; μIR: indirect revascularization.